Syngene’s acquisition of its first US manufacturing facility not due to geopolitical tensions
Indian pharma pivots its operations around green chemistry & sustainable environmental practices
APAC now leads global clinical development of multi-specific antibodies, accounting for over 40% of trials
Syngene sees quantifying a biomarker in mice brain to treat mood and anxiety disorders imperative in drug development
New modalities drive CDMO growth
Rethinking Growth Promoters Through the Lens of Green Chemistry
25 Transformative Years of Biosimilars
Syngene collaborates with biotech firm to develop bile acid modulator for cholestatic disease treatment
Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr
PROTACs: Current Landscape and Their Significance in Drug Discovery
